Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second Compassionate Use Program of ParvOryx in Combination Bevacicumab and Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Patients with Recurrent Glioblastoma without Prior Surgery

Trial Profile

Second Compassionate Use Program of ParvOryx in Combination Bevacicumab and Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Patients with Recurrent Glioblastoma without Prior Surgery

Status: Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; H 1PV (Primary) ; H 1PV (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 09 Sep 2017 Results (n=8) assessing the effect of H-1PV in combination with bevacicumab and nivolumab or pembrolizumab, presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
    • 01 Jun 2017 New trial record
    • 23 May 2017 Preliminary results published in an Oryx GmbH & Co Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top